Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Trouble With Stapled Peptides? A Strong Rebuttal. | Main | A Short Guide to the JP Morgan Conference »

January 14, 2014

A New Metabolism Predictor

Email This Entry

Posted by Derek

Drug metabolism is a perennial topic for us small-molecule people. Watching your lovingly optimized molecules go through the shredding-machine of the liver is an instructive experience, not least when you consider how hard it would be for you to do some of the chemistry that it does. (For reference and getting up to speed on the details, the comments section here has had reader recommendations for the Drug Metabolism and Pharmacokinetics Quick Guide).

Here's a review of a new sites-of-metabolism predictor, FAME, a decision-tree type program that's been trained on data from 20,000 known compounds. It handles both Phase I and Phase II metabolism (a "Pharma 101" entry on that topic is here, for those who'd like to know more), and it looks like it's well worth considering if you're in need for something like this.

Here's my question for the med-chem and PK types: have you made use of predictive metabolism software? Did it save you time, or did you either go down the wrong alleys or not see anything you wouldn't have predicted yourself? I'm interested in real-world experiences, since I haven't had too many myself in this area.

Comments (10) + TrackBacks (0) | Category: In Silico | Pharmacokinetics


COMMENTS

1. Anonymous PK Scientist on January 14, 2014 3:02 PM writes...

I've not used the metabolism prediction programs as much as some of my colleagues that focus specifically on MetID, but when I did use them they never seemed to provide anything useful. I remember evaluating a particular program a couple years back (I won't name the guilty party)...we were feeding it compounds from our library for which metabolites had already been characterized and it either came up with predictions that were blatantly obvious or crazy ones that we never actually saw in vivo. After that, I quit paying attention to metabolite prediction software.

Permalink to Comment

2. Anonymous BMS Researcher on January 14, 2014 10:36 PM writes...

Wonder if this will be much of an improvement on three chemists looking at an SAR matrix of structures and talking rapidly while waving their hands around...

Permalink to Comment

3. Rock on January 14, 2014 11:23 PM writes...

I have never found them to be very useful. As you suggested, they usually predict the obvious primary and sometimes secondary metabolites. However, I do enjoy reading about the exhaustive met ID work on clinical candidates published frequently in DMD (especially when they include human clinical metabolite data). It is often amazing how some compounds can get chewed down to a stub, sometimes requiring 6 or 7 sequential steps. It usually requires radiolabeled drug to identify them all.

Permalink to Comment

4. anon on January 15, 2014 2:22 AM writes...

If it is all so obvious why do people still make compounds with inappropriate PK?

Permalink to Comment

5. Anonymous on January 15, 2014 3:12 AM writes...

@4: Because everything is obvious in hindsight.

Permalink to Comment

6. Tim on January 15, 2014 8:06 AM writes...

@4, because some sites of metabolism are obvious and some are simply unpredictable.

Permalink to Comment

7. annon fore on January 15, 2014 10:04 AM writes...

My former group had tried them and dismissed their value very quickly. I find them to be a one dimensional analysis & predictor while the real PK, metabolism, disposition, and elimination is based on a multidimensional world of biology, biochemistry, and physiology.

Permalink to Comment

8. FAcehiker on January 15, 2014 12:25 PM writes...

The software Meteor,Metasite have been around for a while. They do a pretty good job of using a knowledge base to predict the possible metabolism sites. And there is no reason they won't get better if Samantha and her OS friends start paying attention. The algorithms help the MetID scientist channel his structure proof and help the MedChem scientist model attempts to stabilize a molecule. But they cannot predict metabolic stability, enzyme kinetics is too elastic. Stop one CYP with a fluorine and you turn another one on.

Permalink to Comment

9. LiqC on January 16, 2014 1:26 AM writes...

At some point I will have to put a compound with N-alkylaniline into a mouse. Could someone give a hint of what alkyl group to choose to avoid extensive metabolism?

Would benzyl thioether also be a liability?

I should say I'm not making a drug out of it, this is for tracer purposes. But it would be important for the aniline to persist for at least a few hours.

Permalink to Comment

10. tommy on January 17, 2014 5:01 PM writes...

For house-wife predictions these programs are good enough at an early stage. But do not expect miracles to predict relative ratios of different metabolite a, b, c in species x or y. We are still dealing with rather unspecific enzymes.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern